A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

104

Participants

Timeline

Start Date

June 22, 2022

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2027

Conditions
Muscular DystrophiesMuscular Dystrophy, DuchenneMuscular Disorders, AtrophicMuscular DiseasesNeuromuscular DiseasesGenetic Diseases, X-LinkedGenetic Diseases, InbornNervous System Diseases
Interventions
BIOLOGICAL

Deramiocel (CAP-1002)

Cohort A: CAP-1002A manufactured in Los Angeles, CA; Cohort B: CAP-1002B manufactured in San Diego, CA

BIOLOGICAL

Placebo

Placebo

Trial Locations (20)

22903

University of Virginia Children's Hospital, Charlottesville

27278

Rare Disease Research NC LLC, Hillsborough

30329

Rare Disease Research, LLC, Atlanta

44308

Akron Children's Hospital, Akron

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

52242

University of Iowa Hospitals and Clinics, Iowa City

53226

Children's Wisconsin, Milwaukee

60611

Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago

63110

Saint Louis Children's Hospital, St Louis

65212

University of Missouri Health Care, Columbia

72202

Arkansas Children's Hospital, Little Rock

75207

Children's Health Specialty Care Pavilion, Dallas

80045

Children's Hospital Colorado, Aurora

84112

University of Utah Hospital, Salt Lake City

85016

Phoenix Children's Hospital, Phoenix

90027

Children's Hospital of Los Angeles, Division of Neurology, Los Angeles

92037

UCSD Altman Clinical and Translational Research Institute, La Jolla

95817

University of California, Davis, Sacramento

98105

Seattle Children's, Seattle

02115

Boston Children's Hospital, Boston

All Listed Sponsors
lead

Capricor Inc.

INDUSTRY